Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world

Min Fang; Le Wang; Qing Gu; Huiwen Wu; Xianghui Du; Xiaojing Lai

doi:10.1007/s10585-023-10227-5

Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world

Clin Exp Metastasis. 2023 Oct;40(5):423-429. doi: 10.1007/s10585-023-10227-5. Epub 2023 Aug 16.

Authors

Min Fang^{1

2

3}, Le Wang^{4

5}, Qing Gu^{6

4}, Huiwen Wu⁶, Xianghui Du^{6

4}, Xiaojing Lai^{7

8}

Affiliations

¹ Department of Thoracic Radiotherapy, Key Laboratory of Radiation Oncology of Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, 310022, China. fangmin@zjcc.org.cn.
² Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310018, China. fangmin@zjcc.org.cn.
³ Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou, 310022, China. fangmin@zjcc.org.cn.
⁴ Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310018, China.
⁵ Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
⁶ Department of Thoracic Radiotherapy, Key Laboratory of Radiation Oncology of Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
⁷ Department of Thoracic Radiotherapy, Key Laboratory of Radiation Oncology of Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, 310022, China. laixj@zjcc.org.cn.
⁸ Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310018, China. laixj@zjcc.org.cn.

PMID: 37584783
DOI: 10.1007/s10585-023-10227-5

Abstract

The immunotherapy combined chemotherapy has been the standard treatment strategy for extensive-stage small lung cancer (ES-SCLC). The CREST trial reported consolidative thoracic radiotherapy (cTRT) improved overall survival (OS) for ES-SCLC with intrathoracic residual after chemotherapy. In this study, patients with ES-SCLC who received immunotherapy were assigned to receive either TRT or no TRT. TRT significantly improved progression-free survival (PFS), local recurrence-free survival (LRFS) and OS with well tolerated toxicity. Further sub-cohort analysis, TRT significantly improved LRFS in patients with oligo-metastasis and without liver metastasis.

Keywords: Chemoimmunotherapy; ES-SCLC; Thoracic Radiotherapy; Toxicity.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunotherapy
Lung Neoplasms* / drug therapy
Lung Neoplasms* / radiotherapy
Neoplasm Staging
Small Cell Lung Carcinoma* / drug therapy
Small Cell Lung Carcinoma* / radiotherapy
Treatment Outcome